Evidence map›Paper›PMID 41204125›Full record

ArticleBMC cancer2025

Clinical features and prognostic factors of ovarian cancer brain metastases from ovarian cancer: a retrospective multicenter study of 129 cases.

Yingying Wang, Qiyue Chao, Xiaoyan Lu, Yichi Zhou, Zhiwen Xie, Shiyun Zhang, Fei Xu, Sikao Wu, Lvzhong Hu, Bo Ding and 13 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Yingying WangDepartment of Obstetrics and Gynecology, Division of Life Sciences and Medicine, Core Facility Center, The First Affiliated Hospital of USTC, University of Science and Technology of China, Hefei, China.
Qiyue ChaoDepartment of Obstetrics and Gynecology, Division of Life Sciences and Medicine, Core Facility Center, The First Affiliated Hospital of USTC, University of Science and Technology of China, Hefei, China.
Xiaoyan LuDepartment of Gynecological Oncology, Zhejiang Cancer Hospital, Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, China.
Yichi ZhouDepartment of Gynecological Oncology, Zhejiang Cancer Hospital, Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, China.
Zhiwen XieDepartment of Gynecologic Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Centre, Guangzhou, China.
Shiyun ZhangDepartment of Gynecologic Oncology, Zhongshan Hospital, Fudan University, Shanghai, China.
Fei XuDepartment of Gynecologic Oncology, Fudan University Shanghai Cancer Center, 270 Dong-a Road, Shanghai, China.
Sikao WuDepartment of Obstetrics and Gynecology, West China Second Hospital, Chengdu, China.
Lvzhong HuDepartment of Obstetrics and Gynecology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Bo DingDepartment of Obstetrics and Gynecology, School of Medicine, Zhongda Hospital, Southeast University, Nanjing, China.
Xinyi ZhangDepartment of Gynecologic Oncology, The First Affiliated Hospital of Bengbu Medical University, Bengbu, China.
Tianmin XuDepartment of Gynecology and Obstetrics, The Second Hospital of Jilin University, Changchun, China.
Guantai NiDepartment of Obstetrics and Gynecology, The First Affiliated Hospital of Wannan Medical College, Wuhu, China.
Jing LiangDepartment of Obstetrics and Gynecology, China-Japan Friendship Hospital, Beijing, China.
Jinhua ZhouDepartment of Obstetrics and Gynecology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Yang ShenDepartment of Obstetrics and Gynecology, School of Medicine, Zhongda Hospital, Southeast University, Nanjing, China.
Bo YangDepartment of Gynecologic Oncology, The First Affiliated Hospital of Bengbu Medical University, Bengbu, China.
Shengtao ZhouDepartment of Obstetrics and Gynecology, West China Second Hospital, Chengdu, China.
Xiaojun ChenDepartment of Gynecologic Oncology, Fudan University Shanghai Cancer Center, 270 Dong-a Road, Shanghai, China.
Tingyan ShiDepartment of Gynecologic Oncology, Zhongshan Hospital, Fudan University, Shanghai, China. shi.tingyan@zs-hospital.sh.cn.
Chunyan LanDepartment of Gynecologic Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Centre, Guangzhou, China. lanchy@sysucc.org.cn.
Tao ZhuDepartment of Gynecological Oncology, Zhejiang Cancer Hospital, Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, China. zhutao@zjcc.org.cn.
Ying ZhouDepartment of Obstetrics and Gynecology, Division of Life Sciences and Medicine, Core Facility Center, The First Affiliated Hospital of USTC, University of Science and Technology of China, Hefei, China. caddiezy@ustc.edu.cn.

Funding

Anhui Provincial Key Research and Development Program 2022e07020013National Natural Science Foundation of China 82303588National Natural Science Foundation of China 82473382Natural Science Research Project of Colleges and Universities in Anhui Province 2022AH051255Social Development Project of Public Welfare Technology Research in Zhejiang Province LGF21H160008
6 · The paper itself

Abstract

backgroundOvarian cancer brain metastases (OCBM) are rare and have poor prognosis, with limited clinical management guidelines. This study aimed to identify prognostic factors and optimal treatment approaches for patients with OCBM.

methodsWe conducted a retrospective multicenter analysis of patients with OCBM from 12 hospitals in China from May 2010 to May 2022. The primary outcomes were overall survival (OS) and brain metastasis-specific survival (BMSS). Kaplan-Meier and Cox regression analyses were used to assess treatment outcomes and identify prognostic risk factors.

resultsIn total, 129 patients with OCBM were included. The median interval from ovarian cancer diagnosis to brain metastasis (BM) was 25.74 (range: 0-103.1) months. Headache attributed to BM was the most common presenting symptom, reported in 64 (49.6%) patients, followed by paralysis in 23 (17.8%) patients. The cerebellum and brainstem were the most frequent metastatic sites (36 patients, 27.9%), followed by the frontal lobe (27 patients, 20.9%). In BMSS analysis, multiple BM lesions (hazard ratio [HR]: 2.060; 95% confidence interval [CI]: 1.308-3.244; P = 0.002), headache attributed to BM (HR: 1.765; 95% CI: 1.049-2.968; P = 0.032), and relapse lines before BM diagnosis (HR: 2.060; 95% CI: 1.308-3.244; P = 0.002) were independent predictors of worse BMSS. Subgroup Kaplan-Meier analysis showed that patients with a single BM lesion achieved significantly better outcomes with stereotactic radiosurgery (SRS) compared with those having multiple lesions.

conclusionThis study demonstrates that patients with a single BM lesion may benefit from SRS, whereas those with multiple lesions require more individualized treatment strategies.

Indexed as

Brain NeoplasmsOvarian NeoplasmsAdultAgedAged, 80 and overChinaFemaleHumansKaplan-Meier EstimateMiddle AgedPrognosisRetrospective StudiesBrain metastasisOvarian cancerPrognostic factorStereotactic radiosurgery

Identifiers

PMID41204125
PMCPMC12595899

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.